Navigation Links
Isis Pharmaceuticals to Present at the 14th Annual Bank of America Merrill Lynch Health Care Conference
Date:5/3/2011

CARLSBAD, Calif., May 3, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Bank of America  Merrill Lynch's 14th Annual Health Care Conference on Tuesday, May 10, 2011 at 1:40 p.m. PT at the Encore at the Wynn in Las Vegas.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Optimer Pharmaceuticals Expands Senior Management Team
2. Avanir Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
4. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
5. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
6. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
7. Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
8. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
9. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
10. Inovio Pharmaceuticals to Present at Investor Conferences
11. Endo Pharmaceuticals Reports Strong First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , September 30, 2014 In ... CSF (Cerebrospinal Fluid) backflow of the Eldor spinal needle ... the single hole pencil point spinal needles of the ... Spinal anesthesia is an excellent type of ... Urology, General Anesthesia, etc. It is estimated ...
(Date:9/30/2014)... Sept. 30, 2014  The orthopedic specialists at Midwest ... 6 orthopedic group by US News & World Report, ... series of free, public seminars to discuss partial and ... world come to see the knee physicians at Midwest ... available at Munster Specialty Surgery Center. ...
(Date:9/30/2014)... 2014  Arena Solutions, the pioneer of cloud-based ... Fall 2014 release, which includes two new modules ... DataExtract – and significant enhancements to ... focused specifically on speeding time to market. They ... complete history of tribal knowledge throughout the supply ...
Breaking Medicine Technology:"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 2Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 4
... Calif., Dec. 6, 2011 A new study ... clinics across the United States witnessed opiate prescriptions for ... 2008.  Dr. Michael Lowenstein, co-medical director for the Waismann ... , warns that this increase signals the gaining popularity ...
... a pioneer in the innovative treatment of extracorporeal ... that the first patient has been enrolled in ... of the company,s photopheresis technology in the treatment ... An estimated 15,000 new patients worldwide are diagnosed ...
Cached Medicine Technology:Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 2Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 3First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease 2First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease 3
(Date:9/30/2014)... measure damaging "brain tsunamis" in injured patients without ... to reality, thanks to pioneering research at the ... research team, led by Jed Hartings, PhD, research ... the UC College of Medicine, has shown that ... brain like tsunami wavescan be measured by the ...
(Date:9/30/2014)... apnea is a potential health risk for millions of Americans, ... the disorder: a "fat" tongue. "This is the first ... tongue of obese patients with obstructive sleep apnea," study senior ... the University of Pennsylvania Medical Center, said in a news ... Oct. 1. Sleep apnea is a common disorder in ...
(Date:9/30/2014)... PROVIDENCE, R.I. [Brown University] Autism is no stranger ... the East African nation is access to clinical services, ... autism diagnostic measure, for example, validated for use in ... small new study, however, researchers at Brown University and ... diagnostic approach that they implemented at two sites in ...
(Date:9/30/2014)... WASHINGTON Legislation passed in 2003 to slow the ... government to treat Medicare patients has had no meaningful ... of researchers in the Journal of Clinical Oncology ... of outpatient chemotherapy to treat colorectal and lung cancers, ... oncologists prescribe those drugs following the implementation of the ...
(Date:9/30/2014)... New York, NY (PRWEB) September 30, 2014 ... and falling demand have hampered growth in the ... Popular diets have caused consumers to moderate their ... growing consumer preferences for premium varieties shrunk the ... bread products. Successful operators proactively responded by introducing ...
Breaking Medicine News(10 mins):Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... space technology is helping doctors diagnose and monitor ... its early stages, before it causes heart attacks ... the country are using ArterioVision software initially developed ... along with a standardized, painless, non-invasive ultrasound examination ...
... J. Fox Foundation for Parkinson's Research announced $710,000 in ... leveraging existing data and patient populations to initially characterize ... that may differ in onset, progression and response to ... of Parkinson's disease -- for patients, researchers and clinicians ...
... of concern as most of them are related to mental ... problems due to which people abstained from work. ... Development (CIPD) on about 30,000 workers revealed that mental illness ... muscle related problems like bad back. ,The study ...
... N.J., Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) ... approved a new indication for REMICADE(R) (infliximab) allowing ... (CD) in pediatric patients aged 6 to 17 ... including a corticosteroid, an immunomodulator and primary nutrition ...
... Annual Meeting of the Society for Vascular Surgery, ... worldwide launch of the Cordis AVIATOR (TM) Plus ... for patients with carotid and or renal artery ... and low profile .014 inch rapid exchange (RX) ...
... Ozzy Osbourne says that getting rid of smoking was more ... and alcohol . ,The former hellraiser, who quit ... he has not gotten hooked to smoking again.,He revealed that ... himself with nicotine patches. ,"They're all a b**ger ...
Cached Medicine News:Health News:NASA Technology Helps Detect and Treat Heart Disease and Strokes 2Health News:NASA Technology Helps Detect and Treat Heart Disease and Strokes 3Health News:Michael J. Fox Foundation Awards $710,000 to Understanding of Parkinson's Disease Subtypes 2Health News:Mental Illness Foremost Reason for Absenteeism 2Health News:Remicade(R) Get Approval for First and Only Biologic Treatment for Pediatric Crohn's Disease 2Health News:New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: